Previous Article | Next Article ![]()
Infection and Immunity, September 2000, p. 4884-4892, Vol. 68, No. 9
Center for Vaccine Development, University of
Maryland School of Medicine, Baltimore, Maryland
21201,1 and IRIS, Chiron Spa, Siena,
Italy2
Received 15 February 2000/Returned for modification 6 April
2000/Accepted 12 May 2000
A multivalent live oral vaccine against both Shigella
spp. and enterotoxigenic Escherichia coli (ETEC) is being
developed based on the hypothesis that protection can be achieved if
attenuated shigellae express ETEC fimbrial colonization factors and
genetically detoxified heat-labile toxin from a human ETEC isolate
(LTh). Two detoxified derivatives of LTh, LThK63 and LThR72, were
engineered by substitution
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Attenuated Shigella flexneri 2a Vaccine
Strain CVD 1204 Expressing Colonization Factor Antigen I and Mutant
Heat-Labile Enterotoxin of Enterotoxigenic Escherichia
coli

serine to lysine at residue 63, or lysine
to arginine at residue 72. The genes encoding these two derivatives
were cloned separately on expression plasmids downstream from the CFA/I
operon. Following electroporation into S. flexneri 2a
vaccine strain CVD 1204, coexpression of CFA/I and LThK63 or LThR72 was
demonstrated by Western blot analysis, GM1 binding assays,
and agglutination with anti-CFA/I antiserum. Hemagglutination and
electron microscopy confirmed surface expression of CFA/I. Guinea pigs
immunized intranasally on days 0 and 15 with CVD 1204 expressing CFA/I
and LThK63 or LThR72 exhibited high titers of both serum immunoglobulin
G (IgG) and mucosal secretory IgA anti-CFA/I; 40% of the animals
produced antibodies directed against LTh. All immunized guinea pigs
also produced mucosal IgA (in tears) and serum IgG anti-S.
flexneri 2a O antibodies. Furthermore, all immunized animals were
protected from challenge with wild-type S. flexneri 2a.
This prototype Shigella-ETEC hybrid vaccine demonstrates
the feasibility of expressing multiple ETEC antigens on a single
plasmid in an attenuated Shigella vaccine strain and
engendering immune responses against both the heterologous antigens and
vector strain.
*
Corresponding author. Mailing address: Center for
Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore St., Baltimore, MD 21201. Phone: (410) 706-5328. Fax: (410) 706-6205. E-mail: ebarry{at}medicine.umaryland.edu.
Present address: Wellcome Centre for Human Genetics, Oxford OX3
7BN, United Kingdom.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»